The Guangzhou Sino-Israel Bio-industry Investment Fund (GIBF), which seeks to promote and invest in Chinese and Israeli joint ventures in the biomedical field, said Monday it is raising a second fund for a total of $300 million (2 billion yuan).
The GIBF 2 fund has already closed $200 million, and plans to raise an additional $100 million in the next three months, said Yehoshua (Shuki) Gleitman, a former chief scientist of the State of Israel, who heads the fund.
GIBF typically invests some $3 million-$8 million in the joint venture, holding minority equity positions and assisting the ventures in their operations.
GIBF’s second fund will operate in a similar model to the first fund but will increase its funding to about $15 million-$20 million per venture, and focus on Israeli and European biotechnology companies, which are developing innovative drugs and are in phase 2-3 of clinical trials.
Read more/Source: Times of Israel
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.